[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200870615A1 - Производные лептомицина - Google Patents

Производные лептомицина

Info

Publication number
EA200870615A1
EA200870615A1 EA200870615A EA200870615A EA200870615A1 EA 200870615 A1 EA200870615 A1 EA 200870615A1 EA 200870615 A EA200870615 A EA 200870615A EA 200870615 A EA200870615 A EA 200870615A EA 200870615 A1 EA200870615 A1 EA 200870615A1
Authority
EA
Eurasian Patent Office
Prior art keywords
leptomycin
derivatives
therapeutic use
conjugates
disulfide
Prior art date
Application number
EA200870615A
Other languages
English (en)
Other versions
EA017345B1 (ru
Inventor
Эрве Бушар
Ален Коммерсон
Рави В. Дж. Чари
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37311892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200870615(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of EA200870615A1 publication Critical patent/EA200870615A1/ru
Publication of EA017345B1 publication Critical patent/EA017345B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Описаны производные лептомицина, имеющие группу, такую как сульфидная или дисульфидная, которые могут соединяться со связывающимся с клеткой реагентом, таким как антитела. Описано также терапевтическое применение конъюгатов производного лептомицина; такие конъюгаты находят терапевтическое применение, так как они могут доставлять цитотоксические производные лептомицина к конкретной популяции клеток направленным образом.
EA200870615A 2006-06-09 2007-05-23 Производные лептомицина EA017345B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06290948A EP1864682A1 (en) 2006-06-09 2006-06-09 Leptomycin derivatives
PCT/IB2007/001328 WO2007144709A2 (en) 2006-06-09 2007-05-23 Leptomycin derivatives

Publications (2)

Publication Number Publication Date
EA200870615A1 true EA200870615A1 (ru) 2009-04-28
EA017345B1 EA017345B1 (ru) 2012-11-30

Family

ID=37311892

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870615A EA017345B1 (ru) 2006-06-09 2007-05-23 Производные лептомицина

Country Status (28)

Country Link
US (2) US7816543B2 (ru)
EP (3) EP1864682A1 (ru)
JP (1) JP5162581B2 (ru)
KR (1) KR20090018103A (ru)
CN (2) CN101466409B (ru)
AR (1) AR063668A1 (ru)
AU (1) AU2007258896B2 (ru)
BR (1) BRPI0712899A2 (ru)
CA (1) CA2654322A1 (ru)
CL (1) CL2007001648A1 (ru)
CR (1) CR10459A (ru)
EA (1) EA017345B1 (ru)
EC (1) ECSP088936A (ru)
GT (1) GT200800277A (ru)
HN (1) HN2008001788A (ru)
IL (1) IL195419A0 (ru)
MA (1) MA30689B1 (ru)
ME (1) MEP88208A (ru)
MX (1) MX2008015728A (ru)
MY (1) MY148231A (ru)
NO (1) NO20085127L (ru)
NZ (1) NZ572947A (ru)
SG (2) SG174067A1 (ru)
TN (1) TNSN08463A1 (ru)
TW (1) TWI411609B (ru)
UA (1) UA95959C2 (ru)
WO (1) WO2007144709A2 (ru)
ZA (1) ZA200810015B (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322191B2 (en) 2014-06-30 2019-06-18 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
US11160871B2 (en) 2015-10-28 2021-11-02 Tarveda Therapeutics, Inc. SSTR-targeted conjugates and particles and formulations thereof

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN101732308B (zh) * 2008-11-17 2011-11-30 中国人民解放军军事医学科学院毒物药物研究所 来普霉素b的新用途及含有它的药物组合物和产品
CA2750519C (en) 2009-02-05 2018-09-25 Immunogen, Inc. Benzodiazepine derivatives
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
BR112012020102A2 (pt) 2010-02-10 2016-11-29 Immunogen Inc anticorpos cd20 e usos dos mesmos.
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
CN103687623B (zh) 2011-02-15 2017-06-09 伊缪诺金公司 细胞毒性苯并二氮杂*衍生物
ES2781523T3 (es) 2012-07-12 2020-09-02 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US20150148411A1 (en) * 2013-11-25 2015-05-28 The Rockefeller University Compositions and methods for diagnosis and therapy of disorders related to alterations of myh9
MA43345A (fr) * 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
US10402527B2 (en) 2017-01-04 2019-09-03 Stmicroelectronics S.R.L. Reconfigurable interconnect
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
EP3665161B1 (en) * 2017-08-09 2023-09-27 Helmholtz-Zentrum für Infektionsforschung GmbH New targeted cytotoxic ratjadone derivatives and conjugates thereof
US11531873B2 (en) 2020-06-23 2022-12-20 Stmicroelectronics S.R.L. Convolution acceleration with embedded vector decompression
CN115584329A (zh) * 2022-07-11 2023-01-10 湖北省生物农药工程研究中心 一株链霉菌、其代谢产物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792522A (en) 1983-12-12 1988-12-20 Bristol-Myers Company Rigolettone antitumor complex
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4771070A (en) 1984-08-21 1988-09-13 Warner-Lambert Company CL-1957A antibiotic compound
US4764368A (en) 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
CA2380050A1 (en) * 1999-07-22 2001-02-01 University Of Medicine And Dentistry Of New Jersey Materials and processes for controlled release of thioamide moiety-containing therapeutic agents by linking to thiol-containing polymers
WO2002000024A1 (en) 2000-06-30 2002-01-03 The Regents Of The University Of California New strategy for leukemia therapy
WO2002062396A2 (en) * 2001-02-08 2002-08-15 University Of Medicine And Dentistry Of New Jersey Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US7557189B2 (en) 2002-11-07 2009-07-07 Immunogen Inc. Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
CN102973947A (zh) * 2004-06-01 2013-03-20 健泰科生物技术公司 抗体-药物偶联物和方法
US7446196B2 (en) * 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
US7541330B2 (en) * 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
WO2006135371A1 (en) * 2005-06-09 2006-12-21 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322191B2 (en) 2014-06-30 2019-06-18 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
RU2695220C2 (ru) * 2014-06-30 2019-07-22 Тарведа Терапьютикс, Инк. Нацеленные конъюгаты и частицы и их составы
US10624967B2 (en) 2014-06-30 2020-04-21 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
US11458206B2 (en) 2014-06-30 2022-10-04 Tva (Abc), Llc Targeted conjugates and particles and formulations thereof
US11160871B2 (en) 2015-10-28 2021-11-02 Tarveda Therapeutics, Inc. SSTR-targeted conjugates and particles and formulations thereof

Also Published As

Publication number Publication date
AU2007258896A1 (en) 2007-12-21
EP1864682A1 (en) 2007-12-12
TW200812996A (en) 2008-03-16
EP2032172B1 (en) 2012-06-06
US7816543B2 (en) 2010-10-19
JP2009539820A (ja) 2009-11-19
GT200800277A (es) 2009-06-16
JP5162581B2 (ja) 2013-03-13
EP2032172A2 (en) 2009-03-11
UA95959C2 (en) 2011-09-26
SG174067A1 (en) 2011-09-29
CN102731611A (zh) 2012-10-17
AR063668A1 (es) 2009-02-11
EA017345B1 (ru) 2012-11-30
ZA200810015B (en) 2010-02-24
TWI411609B (zh) 2013-10-11
WO2007144709A3 (en) 2008-06-12
CA2654322A1 (en) 2007-12-21
MY148231A (en) 2013-03-29
CR10459A (es) 2009-01-09
AU2007258896B2 (en) 2013-01-24
NZ572947A (en) 2011-12-22
KR20090018103A (ko) 2009-02-19
US20110002947A1 (en) 2011-01-06
CN101466409A (zh) 2009-06-24
TNSN08463A1 (en) 2010-04-14
CN101466409B (zh) 2012-11-21
EP2540320A1 (en) 2013-01-02
US20090182038A1 (en) 2009-07-16
SG174066A1 (en) 2011-09-29
MA30689B1 (fr) 2009-09-01
IL195419A0 (en) 2009-08-03
BRPI0712899A2 (pt) 2013-01-08
MX2008015728A (es) 2009-01-09
CL2007001648A1 (es) 2008-01-18
HK1134240A1 (en) 2010-04-23
WO2007144709A2 (en) 2007-12-21
HN2008001788A (es) 2012-08-27
ECSP088936A (es) 2009-01-30
MEP88208A (en) 2011-12-20
NO20085127L (no) 2009-01-08

Similar Documents

Publication Publication Date Title
EA200870615A1 (ru) Производные лептомицина
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
NZ620174A (en) Protein kinase conjugates and inhibitors
EA200870327A1 (ru) Улучшенные пролекарства аналогов сс-1065
MX2009004664A (es) Inmunoglobulinas hibridas con partes moviles.
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
EA201070519A1 (ru) Соединения тропана
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
HN2009000379A (es) Anticuerpo especifico prlr y sus usos
NO20091064L (no) Antistoffer mot IL-17A
BRPI0410748B8 (pt) compostos de maitansinóides, suas composições farmacêuticas, métodos de esterificação de maitansinóides, bem como métodos para a sua produção, e conjugado de maitansinóide-agente de ligação celular
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
EA201390642A1 (ru) Цитотоксические агенты, содержащие новые производные анзамитоцина
EP2569330A4 (en) CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF
MY157715A (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
WO2007112193A3 (en) Camptothecin-binding moiety conjugates
UY29727A1 (es) 7-aza-indazoles sustituidos, composiciones que les contienen, procedimientos de fabricación y utilización.
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
EA200801678A1 (ru) Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом
CY1110787T1 (el) Νεα μορφινικα παραγωγα
WO2010009227A3 (en) Recombinant pokeweed antiviral proteins, compositions and methods related thereto
ATE437624T1 (de) Topische zusammensetzungen
UY30235A1 (es) Inhibidores de la adenilato ciclasa soluble

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU